Navigation Links
Lotus Pharmaceuticals Announces Second Quarter 2008 Results
Date:8/18/2008

S

RECONCILIATION OF NON-GAAP FINANCIAL DATA

For the Three Months For the Three Months

Ended Ended

Adjusted Net income June 30, 2008 June 30, 2007

($ in thousands except per

share data) Diluted Diluted

Net Income (Loss) Diluted EPS Net Income EPS Net Income EPS

Adjusted Amount 2,533,555 0.06 3,389,362 0.08

Adjustments

Non cash debt financing

costs (1) 353,646 0.01 347,837 0.01

Amount per consolidated

statement of operations 2,179,909 0.05 3,041,525 0.07

(1) Non cash debt financing costs for Q2 2008 includes amortization of

debt issuance costs of $99,517 and amortization of discount on

convertible redeemable preferred stock of $254,129; Non cash debt

financing costs for Q2 2007 includes amortization of debt issuance

costs of $58,680 amortization of debt discount of $289,157.

For the Six Months For the Six Months

Ended Ended

Adjusted Net income June 30, 2008 June 30, 2007

($ in thousands except per

share data) Diluted Diluted

Net Income (Loss) Diluted EPS Net Income EPS Net Income EPS

Adjusted Amount 3,885,230 0.08 4,400,581 0.10

Adjustments

Non cash debt financing

costs (2) 709,222 0.01 521,755 0.01

Amount per consolidated

statement of operations 3,176,008 0.07 3,878,826 0.09

(2) Non cash debt financing costs for the first half year 2008 includes

'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... (NYSE: MDT ) has submitted a pre-market ... (FDA) for the use of Medtronic,s SynchroMed ® ... catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... Missouri (PRWEB) December 23, 2014 GMO corn ... company, Syngenta, are in the process of being consolidated in ... is In Re: Syngenta AG MIR 162 Corn Litigation, MDL ... of Kansas. , Management of the Syngenta GMO corn multidistrict ...
(Date:12/24/2014)... 23, 2014 The report provides ... definition, classification, application and industry overview. This report ... cost structure. Production is separated by regions, technology ... materials, equipment, downstream client survey, marketing channels, industry ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... MATK ) announced today that life,sDHA(TM), its ... and heart health, is now available to,consumers in ... Challenge,Dairy Products, Inc. Challenge 15 oz. Spreadable Butter ... Founded in 1911, Challenge Dairy Products, Inc., is ...
... Calif., Feb. 4 CV,Therapeutics, Inc. (Nasdaq: ... the companies have entered into an agreement under,which ... technology to develop a drug eluting stent (DES). ... development milestone payments,royalties and other potential payments on ...
... Outside of North ... America, ... facility in Cartago, Costa Rica has been,recognized with the 2008 Shingo Prize ... Prize outside North America,-- is being honored for its achievements in driving ...
Cached Biology Technology:Challenge Spreadable Butter Now Features Martek's life'sDHA(TM) 2Challenge Spreadable Butter Now Features Martek's life'sDHA(TM) 3CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology 2CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology 3Baxter's Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing 2
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... NEW YORK , Jan. 21, 2015  Analyst Report Issued ... Credit Card Brands report showed that planet-wide, transactions at merchants ... 2011, while the total number of credit, debit, and prepaid ... the U.S. were victims of fraudulent card usage in 2012, ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... disabilities who are struggling to regain the use of ... engineers and students from Rochester Institute of Technology. ... the human body, to improve the performance of external ... disabilities, such as strokes or major spinal cord injuries, ...
... know all there is to know about Escherichia coli, ... has more than four thousand genes, and the functions ... Siegele, a biology professor at Texas A&M University whose ... , Harmless E. coli strains are normally found in ...
... Understanding, through its Institute for Arctic Studies, has ... Science Foundation through its Integrative Graduate Education and ... grant supports the development of an interdisciplinary doctoral ... a focus on rapid environmental change. "This grant ...
Cached Biology News:Robotics research: Enhancing the lives of people with disabilities 2GIANT-Coli: A novel method to quicken discovery of gene function 2Dartmouth awarded NSF grant for new polar sciences, engineering grad program 2Dartmouth awarded NSF grant for new polar sciences, engineering grad program 3
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
... off the clot fasted non-Swiss Albino mice of mixed ... N-02: Citrate N-04: Heparin ... Oxalate N-10: EDTA (Na) N-03: ... N-09: K3EDTA N-11: Heparin (K) ...
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
Biology Products: